Conversations in Drug Development Trends

MARCH 20, 2024

In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial.

Clinical Trials 52

Clinical Trials Trials Compliance Treatment 52

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. Ready for more insights into putting the child at the heart of your pediatric clinical trial?

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

PerkinElmer

FEBRUARY 18, 2021

Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings. It is an ongoing debate.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

Conversations in Drug Development Trends

MARCH 12, 2024

For a more in-depth look at biomarkers, check out our white paper. In addition to being well-understood, the methods for collecting non-specific markers of disease burden are frequently cost-effective and robust, enabling your clinical program to collect data seamlessly.

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

Conversations in Drug Development Trends

MARCH 1, 2024

Master protocols allow a trial to perform multiple tests on diverse patient populations or diseases under a unified design. Umbrella Studies Umbrella studies evaluate multiple investigational products (IPs) within a single disease. But how do they work, and when are they appropriate? What Are Master Protocols? Contact us.

Trials 78

Trials Disease Drug Development Clinical Trials 78